Five years into tracking global pre-exposure prophylaxis (PrEP) data, the HIV advocacy organization AVAC has launched a new interactive site that allows users to visualize worldwide country-level information about PrEP use.
Data.prepwatch.org provides visual tools that depict how PrEP uptake has changed over time both within and between countries around the world. The data will be updated every three months.
Truvada (tenofovir disoproxil fumarate/emtricitabine) was first approved as PrEP in the United States in 2012. In the eight years since, the daily HIV prevention pill has been steadily introduced in other nations around the world.
The nonprofit has also issued a primer for PrEP advocates regarding long-acting injectable cabotegravir as PrEP. This investigational HIV prevention method recently performed very well in a randomized, controlled, double-blind, placebo-controlled Phase III trial. It is likely that this form of long-acting injectable PrEP, which is administered every eight weeks by a health care worker, will be available in the United States in 2021.
The cabotegravir primer provides a comprehensive overview of the science behind the new form of PrEP and advises advocates about the key issues to stress when promoting access to this injectable form of HIV prevention.